Torrent Pharmaceuticals Ltd shares gained 3.5 per cent, while Alembic Pharmaceuticals Ltd gained over 6 per cent following USFDA approval for generic versions of blockbuster antipsychotic drug Abilify.
Torrent, Alembic, Hetero Labs and Teva Pharmaceutical Industries Ltd have received the drug regulator's approval.
The product can generate $35-50 million in annualised sales for each company, with high margins, brokerage Motilal Oswal said.